Skip to main content
SpringerLink
Log in

Management of Metastatic Skin Cancers in Organ Transplant Recipients

  • Chapter
Skin Cancer after Organ Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 146))

  • 1185 Accesses

Metastatic skin cancer in the organ transplant population cannot be regarded as a common entity.

The experience of the Royal London Hospital (C.A. Harwood and C.M. Proby, personal communication) is useful to quantify the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clerici M, et al. (1996) The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 88(7): 461–462.

    Article  PubMed  CAS  Google Scholar 

  2. Hrouda D, et al. (1998) Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). BJU Int 82(4): 568–573.

    Article  CAS  Google Scholar 

  3. Maraveyas AD, et al. (1999) Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interkukin-2 in peripheral blood lymphocytes. Ann Oncol 10(7): 817–824.

    Article  PubMed  CAS  Google Scholar 

  4. Ryken T, et al. (2004) Evidence-based review of the surgical management of vertebral column metastatic disease. First retrieved 01/05/2004, 2004, from http://www.medscape.com/viewarticle/465373.

  5. Campistol JM, et al. (2007) Use of proliferation signal inhibitors in the management of post-transplant malignancies: clinical guidance. Nephrol Dial Transplant 22(suppl_1): i36–i41.

    Article  PubMed  CAS  Google Scholar 

  6. De Graaf YGL, et al. (2004) Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 30(4p2): 656–661.

    Article  PubMed  Google Scholar 

  7. Anonymous (2006) Improving Outcomes Guidance for People with Skin Tumours including Melanoma. London: National Institute for Health and Clinical Excellence.

    Google Scholar 

  8. West J, et al. (2005) Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial where both groups are managed according to a strict protocol. Qual Saf Health Care 14(3): 175–178.

    Article  PubMed  CAS  Google Scholar 

  9. Martinez J-C, et al. (2004) Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg 30(4 pt 2): 679–686.

    Article  PubMed  Google Scholar 

  10. Tessmer CS, et al. (2006) Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 82(12): 1792–1793.

    Article  PubMed  Google Scholar 

  11. de Fijter JW (2007) Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 22(suppl_1): i23–i26.

    Article  PubMed  CAS  Google Scholar 

  12. Lippman S, et al. (1992) 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235–241.

    Article  PubMed  CAS  Google Scholar 

  13. Shin D, et al. (2002) Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2): 322–330.

    Article  PubMed  CAS  Google Scholar 

  14. Stasko T, et al. (2004) Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 30(4 pt 2): 642–650.

    Article  PubMed  Google Scholar 

  15. Khansur T, Kennedy A (1991) Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 67(8): 2030–2032.

    Article  PubMed  CAS  Google Scholar 

  16. Sadek H, et al. (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66(8): 1692–1696.

    Article  PubMed  CAS  Google Scholar 

  17. Guthrie TJ, et al. (1985) Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 55(8): 1629–1632.

    Article  PubMed  Google Scholar 

  18. Shin D, et al. (1998) Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 25(2 Suppl 4): 40–44.

    PubMed  CAS  Google Scholar 

  19. Cartei G, et al. (2000) Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23(2): 181–184.

    Article  PubMed  CAS  Google Scholar 

  20. Pfeiffer P, et al. (1989) Chemotherapy in basal cell carcinoma. Complete remission of locally advanced basal cell carcinoma following treatment with chemotherapy containing cis-platinum. Ugeskr Laeg 151(34): 2150–2151.

    PubMed  CAS  Google Scholar 

  21. Pfeiffer P, et al. (1990) Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 26(1): 73–77.

    PubMed  CAS  Google Scholar 

  22. Neudorfer M, et al. (1993) Cisplatin and doxorubicin for invasive basal cell carcinoma of the eyelids. Ann Ophthalmol 25(1): 11–13.

    PubMed  CAS  Google Scholar 

  23. Chimenti S, et al. (1995) Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 190(3): 214–217.

    Article  PubMed  CAS  Google Scholar 

  24. Campistol JM, et al. (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17(2): 581–589.

    Article  PubMed  CAS  Google Scholar 

  25. Zmonarski S, et al. (2005) Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37(2): 964–966.

    Article  PubMed  CAS  Google Scholar 

  26. Campistol JM, Schena FP (2007) Kaposi’s sarcoma in renal transplant recipients: the impact of proliferation signal inhibitors. Nephrol Dial Transplant 22(suppl_1): i17–i22.

    Article  PubMed  CAS  Google Scholar 

  27. Walmsley S, et al. (1999) Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 22(3): 235–246.

    PubMed  CAS  Google Scholar 

  28. Bodsworth N, et al. (2001) Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol 2(2): 77–87.

    Article  PubMed  CAS  Google Scholar 

  29. Hauschild A, Petres-Dunsche C (1992) Intralesional treatment of classical Kaposi sarcoma with interferon-alpha. Hautarzt 43(12): 789–791.

    PubMed  CAS  Google Scholar 

  30. Flaitz C, et al. (1995) Role of intralesional vinblastine administration in treatment of intraoral Kaposi’s sarcoma in AIDS. Eur J Cancer B Oral Oncol 31B(4): 280–285.

    Article  PubMed  CAS  Google Scholar 

  31. Odom R, Goette D (1978) Treatment of cutaneous Kaposi’s sarcoma with intralesional vincristine. Arch Dermatol 114(11): 1693–1694.

    Article  PubMed  CAS  Google Scholar 

  32. Poignonec S, et al. (1995) Intralesional bleomycin for acquired immunodeficiency syndrome-associated cutaneous Kaposi’s sarcoma. Arch Dermatol 131(2): 228.

    Article  PubMed  CAS  Google Scholar 

  33. Fife K, et al. (1998) Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titre. Int J STD AIDS 9:751–755.

    Article  PubMed  CAS  Google Scholar 

  34. Little RF, et al. (2000) Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 18(13): 2593–2602.

    PubMed  CAS  Google Scholar 

  35. Northfelt DW, et al. (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7): 2445–2451.

    PubMed  CAS  Google Scholar 

  36. Stewart S, et al. (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16(2): 683–691.

    PubMed  CAS  Google Scholar 

  37. Laubenstein L, et al. (1984) Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 2(10): 1115–1120.

    PubMed  CAS  Google Scholar 

  38. Brambilla L, et al. (1994) Mediterranean Kaposi’s sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer 74(10): 2873–2878.

    Article  PubMed  CAS  Google Scholar 

  39. Lim S, et al. (2005) Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 103(2): 417–421.

    Article  PubMed  CAS  Google Scholar 

  40. Guba M, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2): 128–135.

    Article  PubMed  CAS  Google Scholar 

  41. Margolin K, et al. (2005) CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104(5): 1045–1048.

    Article  PubMed  CAS  Google Scholar 

  42. Rao R, et al. (2006) Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. J Clin Oncol 24(18S): 8043.

    Google Scholar 

  43. Romano MF, et al. (2004) Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 40(18): 2829–2836.

    Article  PubMed  CAS  Google Scholar 

  44. Sampson J, et al. (1998) Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11–20.

    Article  PubMed  CAS  Google Scholar 

  45. Fife K, et al. (2004). Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7): 1293–1300.

    Article  PubMed  CAS  Google Scholar 

  46. Agrawal S, et al. (1999) Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol 6(4): 336–344.

    Article  PubMed  CAS  Google Scholar 

  47. Gutman H, et al. (2001) Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25(6): 750–758.

    Article  PubMed  CAS  Google Scholar 

  48. Wood T, et al. (2001) Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 8(8): 658–662.

    Article  PubMed  CAS  Google Scholar 

  49. Ollila D, et al. (1998) Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma [see comment]. J Surg Oncol 69(4): 206–211.

    Article  PubMed  CAS  Google Scholar 

  50. Morris SL, et al. (2004) A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 91(5): 829–833.

    PubMed  CAS  Google Scholar 

  51. Gaudy-Marqueste C, et al. (2006) Gamma-knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 65(3): 809–816.

    PubMed  Google Scholar 

  52. Samlowski WE, et al. (2007) Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer 109(9): 1855–1862.

    Article  PubMed  Google Scholar 

  53. Middleton M, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1): 158–166.

    PubMed  CAS  Google Scholar 

  54. Kiebert G, et al. (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21(6): 821–829.

    Article  PubMed  CAS  Google Scholar 

  55. Agarwala S, et al. (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22:2101–2107.

    Article  PubMed  CAS  Google Scholar 

  56. Legha S (1997) The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 24(Suppl 4): S24–S31.

    PubMed  CAS  Google Scholar 

  57. Suranyi M, et al. (1998) Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 66(5): 655–661.

    Article  PubMed  CAS  Google Scholar 

  58. Phan G, et al. (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19(15 3477–3482).

    PubMed  CAS  Google Scholar 

  59. Ridolfi R, et al. (2002) Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20(6): 1600–1607.

    Article  PubMed  CAS  Google Scholar 

  60. Bajetta E, et al. (2006). Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 17(4): 571–577.

    Article  PubMed  CAS  Google Scholar 

  61. Maker AV, et al. (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29(4): 455–463.

    Article  PubMed  CAS  Google Scholar 

  62. Eisen T, et al. (2007) An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol 25(18S): 8529.

    Google Scholar 

  63. Eiling S, et al. (2002) Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 147:150–153.

    Article  PubMed  CAS  Google Scholar 

  64. Fata F, et al. (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86(10): 2034–2037.

    Article  PubMed  CAS  Google Scholar 

  65. Fiore M, et al. (2005) Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 23(30): 7669–7675.

    Article  PubMed  Google Scholar 

  66. Sjoblom T, et al. (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61(15): 5778–5783.

    PubMed  CAS  Google Scholar 

  67. Rubin BP, et al. (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20(17): 3586–3591.

    Article  PubMed  CAS  Google Scholar 

  68. Plunkett T, et al. (2001) Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol 12(3): 411–414.

    Article  PubMed  CAS  Google Scholar 

  69. Huet P, et al. (1996) Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol 35(5 pt 2): 860–864.

    Article  PubMed  CAS  Google Scholar 

  70. Gonzalez-Lopez M, et al. (2003) Metastatic eccrine porocarcinoma: a 5.6-year follow-up study of a patient treated with a combined therapeutic protocol. Dermatol Surg 29(12): 1227–1232.

    Article  PubMed  Google Scholar 

  71. de Bree E, et al. (2004) Treatment of advanced malignant eccrine poroma with locoregional chemotherapy. Br J Dermatol 152:1051–1055.

    Article  Google Scholar 

  72. Gutermuth J, et al. (2004) Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Vener 18(4): 477–479.

    Article  CAS  Google Scholar 

  73. Roach M III (1983) A malignant eccrine poroma responds to isotretinoin (13-cis-retinoic acid). Ann Intern Med 99(4): 486–488.

    PubMed  Google Scholar 

  74. Morgan D, et al. (1987) Vincristine and etoposide: an effective chemotherapy regimen with reduced toxicity in extensive small-cell lung cancer. Eur J Cancer Clin Oncol 23(6): 619–621.

    Article  PubMed  CAS  Google Scholar 

  75. Tai P, et al. (2000) Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18(12): 2493–2499.

    PubMed  CAS  Google Scholar 

  76. Voog E, et al. (1999) Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85(12): 2589–2595.

    Article  PubMed  CAS  Google Scholar 

  77. Poulsen M, et al. (2003) High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans Tasman Radiation Oncology Group Study – TROG 96:07. J Clin Oncol 21(23): 4371–4376.

    Article  PubMed  CAS  Google Scholar 

  78. Robson R, et al. (2003) Risk of PTLD and other malignancies in renal transplant patients treated with MMF: a prospective observational cohort study. Am J Transplant 3(s5): 187.

    Google Scholar 

  79. Pascual J (2007) Post-transplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 22(suppl_1): i27–i35.

    Article  PubMed  CAS  Google Scholar 

  80. Rupoli S, et al. (1999) Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica 84(9): 809–813.

    PubMed  CAS  Google Scholar 

  81. Chiarion-Sileni V, et al. (2002) Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 95(3): 569–575.

    Article  PubMed  CAS  Google Scholar 

  82. Thomsen K, et al. (1989) Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Dermatol Venereol 69(6): 536–538.

    CAS  Google Scholar 

  83. Stadler R, et al. (1998) Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92(10): 3578–3581.

    PubMed  CAS  Google Scholar 

  84. Duvic M, et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II–III trial results. J Clin Oncol 19:2456–2471.

    PubMed  CAS  Google Scholar 

  85. Tsai DE, et al. (2005) Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. Am J Transplant 5(8): 2070–2073.

    Article  PubMed  Google Scholar 

  86. Garber K (2001) Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst 93(20): 1519.

    Article  PubMed  CAS  Google Scholar 

  87. Euvrard S, et al. (2004) Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 30(4 pt 2): 628–633.

    Article  PubMed  Google Scholar 

  88. Witzig TE, et al. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23(23): 5347–5356.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospitals of Leicester, Leicester, UK

    Steve Nicholson

Authors
  1. Steve Nicholson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Dermatologie Venerologie und Allergologie, Charité - Universitätsklinikum Berlin Charite Campus Mitte Klinik und Poliklinik for Dermatologie, Charitéplatz 1, 10117 Berlin, Germany

    Eggert Stockfleth MD, PhD  & Claas Ulrich  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Nicholson, S. (2009). Management of Metastatic Skin Cancers in Organ Transplant Recipients. In: Stockfleth, E., Ulrich, C. (eds) Skin Cancer after Organ Transplantation. Cancer Treatment and Research, vol 146. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-78574-5_39

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-78574-5_39

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-78573-8

  • Online ISBN: 978-0-387-78574-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation